Menu

Macchiarini May Face Involuntary Manslaughter Charges

The embattled stem cell researcher faces a new investigation exploring his culpability in the deaths of two patients he treated.

Jun 23, 2016
Bob Grant

PIXABAY, DEBORABALVESThe artificial organ researcher who was fired from Sweden’s Karolinska Institute earlier this year has been charged with involuntary manslaughter for the deaths of two of his patients, upon whom he performed artificial trachea transplants, according to Swedish prosecutors. After years of ethical inquiries into his research and clinical practice, Paolo Macchiarini was informed last week of the criminal investigation that may end in formal charges of involuntary manslaughter. The investigation will likely center on two patients Macchiarini treated in the U.S.: one a 2-year-old girl who died in 2013, several months after the procedure; the other, an adult male in Baltimore, who died in 2011, three months after his surgery.

“Of course with the accusations that were made against me last year the prosecutor has to investigate, and I have been very happy to give them any information that they need for that investigation,” Macchiarini told the Associated Press in an email.

If Macchiarini is charged with aggravated involuntary manslaughter, he could face between six months and six years in prison.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.